CA9 and neoplasm: In an ex vivo perfusion study, the potential of the hybrid carbonic anhydrase IX (CAIX) targeting antibody-based tracer 111In-girentuximab-IRDye800CW was shown for visualization of the tumor within the kidney with a high sensitivity [41].